DrRoss Macdonald, Cynata's Chief Executive Officer, said: "A cleared IND represents a very significant achievement for any pharmaceutical or biotech company and underpins a major valuation catalyst; I would like to thank our shareholders for their patience during this process. We are delighted to have crossed this threshold and will continue to leverage the momentum in our negotiations with study centres with an expectation to commence a US trial in aGvHD by the end of the year."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)